DiMarchi, who was a vice president at Eli Lilly and involved in GLP-1 research there, until he left the company in 2003, is that many diseases may share the same root causes, even though we label them and treat them as distinct: This is an endocrine disease, this is a cardiovascular disease, this is a brain disease. This root-cause theory suggests that a wide range of conditions can be treatable with one drug class, sometimes through pathways in the brain and the immune system
Initial weight loss with GLP-1 receptor agonists typically becomes noticeable within the first 48 weeks of treatment, though the timeline varies considerably between individuals
GI symptoms typically fade to a background level
Oral semaglutide vs injectable GLP-1 receptor agonists: persistence and adherence in a real-world cohort
Only about 20 percent report a decline, but most say no change
PT-141 peptide is prescribed to help men with erectile dysfunction or low libido, particularly when caused by psychological factors